Bipolar drug Lamictal tied to birth defects when used by expectant mothers

Email this article to a friend

Printable Version

Articles Related to This Article: • Blood-Pressure Drugs Linked to Birth Defects (press release) • Elevated Risk of Birth Defects Found in Women With Pre-Pregnancy Diabetes • Unmasking nutrition's role in genes and birth defects (press release) Support NaturalNews advertisers - Advertise with NaturalNews Help support NaturalNews with health books and educational programs from Truth Publishing: • Swine Flu Advanced Preparedness • 8 Weeks to Vibrant Health • Raw In Ten Minutes (recipes) • How to Halt Diabetes in 25 Days ... and much more.

(NaturalNews) The U.S. Food and Drug Administration announced Friday that expectant mothers taking GlaxoSmithKline's epilepsy and bipolar disorder drug Lamictal could experience a higher rate of birth defects than women not taking the drug.

A recent registry of 564 pregnant women who took Lamictal during their first trimester showed that five women gave birth to babies with cleft lip or cleft palate -- a gap in the upper lip or roof of the child's mouth. The FDA recently posted a safety alert on its website warning that women who are pregnant and taking Lamictal should consult with their doctor, though the agency says more verifiable data is needed to prove the connection. The alert noted that similar registries had not recorded such a high rate of cleft lip and palate incidences in the past.

FDA critic and nutrition author Mike Adams says the FDA is dragging its feet in pulling a potentially dangerous drug off the market. "That the FDA continues to allow psychotropic drugs to be prescribed to expectant mothers is an outrage," Adams said.

British drug giant GlaxoSmithKline says it learned of the registry's results in December 2005, when it notified the FDA of the problem. In June of this year, Glaxo sent a letter to doctors explaining the registry's findings.

"What the North American registry found hasn't been replicated by other pregnancy registries," said Holly Russell, director of product communications for Glaxo. "It's FDA's position as well as our own that without confirming data the important thing is to continue to monitor data from ongoing pregnancy registries and other sources."

GlaxoSmithKline announced last week that the FDA had recently approved Lamictal -- which brought in profits of $1.34 million for the company last year -- for treating epilepsy patients who suffer grand mal seizures, in addition to treating other epileptic disorders and bipolar disorder.

However, Adams says all consumers taking the drug should be aware of potential dangers, especially pregnant women or women who may become pregnant. "These drugs cause permanent harm to the fetus, resulting in birth defects, stunted development and enormous future health care costs," he said.

###

Share

Get articles like this delivered to you FREE in our popular email newsletter

Related CounterThink Cartoons:

Related Articles: • Blood-Pressure Drugs Linked to Birth Defects (press release) • Elevated Risk of Birth Defects Found in Women With Pre-Pregnancy Diabetes • Unmasking nutrition's role in genes and birth defects (press release)	Take Action: Support NaturalNews.com Email this article to a friend Share this article on: NewsVine | digg | del.icio.us Permalink to this article: http://www.NaturalNews.com/020602_birth_defects_GlaxoSmithKline_bipolar_disorder.html Reprinting this article: Non-commercial use OK, cite NaturalNews.com with clickable link. Embed article link: (copy HTML code below): <a href = "http://www.NaturalNews.com/020602_birth_defects_GlaxoSmithKline_bipolar_disorder.html">Bipolar drug Lamictal tied to birth defects when used by expectant mothers</a>